&lt;p&gt;Targeting IL-5 in COPD&lt;/p&gt;

Narendra, Dharani Kumari; Hanania, Nicola A.

doi:10.2147/copd.s155306

Cited by 39 publications

(33 citation statements)

References 32 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A subset of COPD patients present with a predominantly IL-5 mediated eosinophilic inflammation, which has shown to contribute to exacerbation frequency and lung function decline [ 142 , 143 , 144 ]. IL-5 mediated eosinophilic inflammation plays a critical role in asthma [ 142 , 145 , 146 ] and treatments with mepolizumab [ 147 ] and reslizumab [ 148 ], which both target IL-5, are approved for asthma therapy.…”

Section: Anti-aging Treatment Strategies In Copdmentioning

confidence: 99%

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

Easter

Bollenbecker

Barnes

et al. 2020

IJMS

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) has become a global epidemic and is the third leading cause of death worldwide. COPD is characterized by chronic airway inflammation, loss of alveolar-capillary units, and progressive decline in lung function. Major risk factors for COPD are cigarette smoking and aging. COPD-associated pathomechanisms include multiple aging pathways such as telomere attrition, epigenetic alterations, altered nutrient sensing, mitochondrial dysfunction, cell senescence, stem cell exhaustion and chronic inflammation. In this review, we will highlight the current literature that focuses on the role of age and aging-associated signaling pathways as well as their impact on current treatment strategies in the pathogenesis of COPD. Furthermore, we will discuss established and experimental COPD treatments including senolytic and anti-aging therapies and their potential use as novel treatment strategies in COPD.

show abstract

Section: Anti-aging Treatment Strategies In Copdmentioning

confidence: 99%

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

Easter

Bollenbecker

Barnes

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…COPD is characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases [30]. It is estimated that up to 40% of patients with COPD have eosinophilic inflammation [31,32], and approximately 20% of exacerbations have been identified as eosinophilic exacerbations [33][34][35]. The role of eosinophils in COPD may differ notably from that in asthma and other diseases [36].…”

mentioning

confidence: 99%

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Jackson

Korn²,

Mathur

et al. 2020

Drug Saf

View full text Add to dashboard Cite

Eosinophils play a pivotal role in the inflammatory pathology of asthma and have been the target of new biologic treatments for patients with eosinophilic asthma. Given the central role of interleukin (IL)-5 in the eosinophil lifecycle, several therapies directed against the IL-5 pathway have been developed, including the anti-IL-5 antibodies mepolizumab and reslizumab and the IL-5 receptor α (IL-5Rα)-directed cytolytic antibody benralizumab. Eosinophil-depleting therapies represent a relatively new class of asthma treatment, and it is important to understand their long-term efficacy and safety. Eosinophils have been associated with host protection and tumor growth, raising potential concerns about the consequences of long-term therapies that deplete eosinophils. However, evidence for these associations in humans is conflicting and largely indirect or based on mouse models. Substantial prospective clinical trial and postmarketing data have accrued, providing insight into the potential risks associated with eosinophil depletion. In this review, we explore the current safety profile of eosinophil-reducing therapies, with particular attention to the potential risks of malignancies and severe infections and a focus on benralizumab. Benralizumab is an IL-5Rα-directed cytolytic monoclonal antibody that targets and efficiently depletes blood and tissue eosinophils through antibody-dependent cell-mediated cytotoxicity. Benralizumab is intended to treat patients with severe, uncontrolled asthma with eosinophilic inflammation.

show abstract

“…Elevated eosinophil numbers are considered major biomarkers of asthma [22]. Eosinophilia during asthma development is associated with pro-inflammatory cytokines such as IL-4, IL-5 and IL-13 [23,24]. These cytokines are involved in driving the maturation, activation, and accumulation of eosinophils within damaged lung lesions, leading to IgE production, airway inflammation, mucus overproduction, and AHR [25,26].…”

Section: Discussionmentioning

confidence: 99%

Scrophularia koraiensis Nakai Attenuates Allergic Airway Inflammation via Suppression of NF-κB and Enhancement of Nrf2/HO-1 Signaling

et al. 2020

View full text Add to dashboard Cite

Scrophularia koraiensis Nakai (Scrophulariaceae) is a medicinal herb that grows in Korea and which has been widely used to treat fever, edema, neuritis and laryngitis. Hence, we evaluated the anti-inflammatory and antioxidant effects of the ethanol extract (SKE) of S. koraiensis Nakai in an ovalbumin (OVA)-induced mouse model. We injected 20 μg of OVA with 2 mg of aluminum on day 0 and day 14 to induce allergic airway inflammation in six-week-old BALB/c mice, and mice were challenged with 1% OVA by nebulization for 1 h on days 21, 22, and 23. SKE was orally administered at 20 mg/kg and 40 mg/kg from day 18 to 23, and its effects were compared with those of montelukast treatment. SKE significantly reduced proinflammatory cytokines, inflammatory cell counts, immunoglobulin-E, and airway hyperresponsiveness during the OVA-induced allergic airway inflammation model; it also reduced airway inflammation and mucus production. In addition, SKE reduced the OVA-induced nuclear factor kappa B (NF-κB) phosphorylation in lung tissues while enhancing nuclear factor erythroid-derived 2-related factor (Nrf-2) and heme oxygenase-1 (HO-1) expression. In conclusion, SKE showed the protective effects on OVA-induced allergic airway inflammation via the suppression of NF-κB phosphorylation and the enhancement of the Nrf2/HO-1 signaling pathway. These results indicate that SKE is a potential therapeutic agent for allergic airway inflammation.

show abstract

<p>Targeting IL-5 in COPD</p>

Cited by 39 publications

References 32 publications

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

Targeting Aging Pathways in Chronic Obstructive Pulmonary Disease

Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab

Scrophularia koraiensis Nakai Attenuates Allergic Airway Inflammation via Suppression of NF-κB and Enhancement of Nrf2/HO-1 Signaling

Contact Info

Product

Resources

About